Estropipate
"Ogen" redirects here. For the character in the Japanese anime, see Ogen (Basilisk).
![]() | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Monograph |
| ATC code | none |
| Identifiers | |
| |
| CAS Number |
7280-37-7 |
| PubChem (CID) | 5284555 |
| DrugBank |
DB04574 |
| ChemSpider |
4447610 |
| UNII |
SVI38UY019 |
| KEGG |
D00948 |
| ChEMBL |
CHEMBL1200980 |
| Chemical and physical data | |
| Formula | C22H32N2O5S |
| Molar mass | 436.56 g/mol |
| 3D model (Jmol) | Interactive image |
| |
| |
| | |
Estropipate (INN, USAN, BAN) (brand names Harmogen, Improvera, Ogen, Ortho-Est, many others), also known as piperazine estrone sulfate, is a semi-synthetic, steroidal estrogen that is used mainly in hormone replacement therapy in the treatment of symptoms of menopause.[1][2] It is a salt of estrone sulfate and piperazine, and is hydrolyzed into estrone in the body.[1][2]
Uses
Estropipate is used to:
- Alleviate symptoms of menopause as hormone replacement therapy
- Treat some types of infertility
- Treat some conditions leading to underdevelopment of female sexual characteristics
- Treat vaginal atrophy
- Treat some types of breast cancer (particularly in men and postmenopausal women)
- Treat prostate cancer
- Prevent osteoporosis
Pharmacology
Estropipate is an agonist of the estrogen receptor (ER). In addition, estropipate has been found to act as an inhibitor of SLCO1B1 (OATP1B1) (IC50 = 70 nM).
See also
References
- 1 2 J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 900–. ISBN 978-1-4757-2085-3.
- 1 2 I.K. Morton; Judith M. Hall (6 December 2012). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 114–. ISBN 978-94-011-4439-1.
This article is issued from Wikipedia - version of the 10/1/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
